相关实验视频
Updated: Jun 9, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.3K
初级阿尔多斯特主义预测模型对二次高血压的影响支持决策
Peter B Mack1,2, Casey Cole3, Mintaek Lee3
1Institute of Quality and Safety, Novant Health, Winston-Salem, NC 27103, United States.
JAMIA open
|October 30, 2024
概括
在临床决策支持中整合一次性阿尔多斯特隆症 (PA) 预测模型,在初级保健中显著增加了PA查. 这种增强解决了PA的不足选问题,通过更好的诊断实践改善了患者护理.
科学领域:
- 内部医学 内部医学
- 心脏病学 心脏病学
- 临床决策支持系统 临床决策支持系统
背景情况:
- 原发性阿尔多斯特隆症 (PA) 是二次高血压的常见但未被确诊的原因.
- 目前在初级保健中对PA的查实践往往不足,导致诊断和治疗延迟.
- 临床决策支持 (CDS) 工具可以帮助识别各种疾病的风险患者.
研究的目的:
- 评估将PA预测模型纳入二次高血压CDS工具是否可以提高初级保健机构内PA查率.
- 评估预测模型对使用PA诊断测试的影响.
主要方法:
- 一项涉及153家初级保健诊所的随机试验于2023年8月至2024年4月期间进行.
- 诊所被分配给接受二次高血压CDS工具,有或没有集成的PA预测模型.
- 该研究分析了基于患者风险分数的订单集的启动和阿尔多与雷宁比率 (ARR) 测试的订单.
主要成果:
- 与对照诊所相比,使用PA预测模型的诊所在订单启动和ARR订单方面呈现出统计学上显著的增加.
- 对于风险最高的患者 (前1百分位),在模型诊所中,ARR在0.66%的病例中被订购,而在没有模型诊所中则为0.0% (P=.010).
- 在所有患者中,ARR排序从没有模型诊所的0.19%增加到模型诊所的0.61% (P<.001).
结论:
- 将PA预测模型集成到二次高血压CDS工具中,大大改善了初级保健中PA的查.
- 这种方法有效地解决了目前PA的查不足问题,可能导致更早的诊断和管理.
- 用预测模型来增强传统的CDS对未得到充分查的疾病是改善医疗保健结果的可行策略.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
499
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
499
Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
Antihypertensive Drugs: Potassium-Sparing Diuretics
464
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
464
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
485
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
485

